Annals
Established in 1927 by the American College of Physicians
:
Advanced search
 
box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Lam, S.
space
  arrow  Bank, S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

LETTER

Hepatotoxicity Caused by Metronidazole Overdose

right arrow Sing Lam and Simmy Bank

15 May 1995 | Volume 122 Issue 10 | Page 803


TO THE EDITOR:

The most frequently reported adverse effects of metronidazole include gastrointestinal symptoms such as nausea, vomiting, metallic taste, abdominal discomfort, and diarrhea. More serious side effects include reversible peripheral neuropathy, convulsions, and blood dyscrasias [1]. To our knowledge, only one suspected case of metronidazole-induced hepatotoxicity has been reported in the English-language literature [2].

We recently encountered a patient who developed drug-induced hepatitis caused by metronidazole overdose. A 58-year-old-woman was hospitalized in October 1994 because of dizziness and fainting. Her medical history included chronic depressive illness. She also had chronic low-back pain and insomnia. She had had lumbosacral laminectomy 2 years earlier, a procedure that was complicated by a delayed lumbar spinal abscess that required prolonged drainage and long-term oral antibiotic therapy, including oral metronidazole. The night before her hospitalization, she had taken about 12.5 g of metronidazole that remained from her abscess therapy. She denied taking any other medications, particularly aspirin and acetaminophen. Her physical examination on admission showed evidence of depression. She had tenderness at the lumbosacral surgical wound site. No jaundice or other signs of hepatic disease were present, and an abdominal examination was normal. Her blood cell counts were within normal limits. Initially, her liver function test results were moderately elevated (Table 1). Drug screens for acetaminophen, salicylate, tricyclic antidepressants, opiates, barbiturates, benzodiazepines, phencyclidine, and other drugs were negative. A serologic profile for viral hepatitis showed positive results only for hepatitis A IgG. An abdominal sonogram of the biliary tract was normal. During the next 5 days her symptoms of anorexia and nausea improved.


View this table:
[in this window]
[in a new window]
 
Table 1. Liver Function Test Results in a Patient with Metronidazole Hepatotoxicity*

 

Metronidazole has not previously been associated with hepatotoxicity, despite wide clinical use of the drug. The agent is primarily metabolized by the liver [3] and is safe if used in regular doses. Metronidazole overdose can cause hepatotoxicity, as shown by our patient. Although no liver biopsy was done, the clinical situation, temporal sequence of the event, and absence of ingestion of an alternate hepatotoxic drug implicate metronidazole.


Author and Article Information
space
up arrowTop
dotAuthor & Article Info
down arrowReferences

Long Island Jewish Medical Center, New Hyde Park, NY 11040.


References
space
up arrowTop
up arrowAuthor & Article Info
dotReferences

1. Goldman P. Metronidazole. N Engl J Med. 1980; 303:212-8.

2. Appleby DH, Vogyland HD. Suspected metronidazole hepatotoxicity. Clin Pharmacol. 1983; 2:373-4.

3. Brogden RN, Heel RC, Speigt TM. Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use. Drugs. 1978; 16:387-417.

About Letters
space

The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:

•Include no more than 300 words of text, three authors, and five references

•Type with double-spacing

•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.

Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.

Annals welcomes electronically submitted letters.




This article has been cited by other articles:


Home page
Am J Health Syst PharmHome page
A. M. Rivkin
Hepatocellular enzyme elevations in a patient receiving ceftriaxone
Am. J. Health Syst. Pharm., October 1, 2005; 62(19): 2006 - 2010.
[Full Text] [PDF]


box Article
 arrow  Table of Contents                
space
 arrow  Figures/Tables List
space
 arrow  Articles citing this article
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Lam, S.
space
  arrow  Bank, S.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space


 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online